PepGen (PEPG) announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered by PepGen. PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes. Leerink Partners and Stifel are acting as joint book-running managers for the proposed offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEPG:
- PepGen says FREEDOM clinical study achieves all key objectives
- PepGen initiated with a Buy at Guggenheim ahead of DM1 data
- PepGen initiated with a Buy at Guggenheim
- PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating
- PepGen Inc. Reports Q2 2025 Financial Results